全文获取类型
收费全文 | 735篇 |
免费 | 29篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 17篇 |
儿科学 | 24篇 |
妇产科学 | 13篇 |
基础医学 | 120篇 |
口腔科学 | 12篇 |
临床医学 | 57篇 |
内科学 | 78篇 |
皮肤病学 | 10篇 |
神经病学 | 36篇 |
特种医学 | 24篇 |
外科学 | 129篇 |
综合类 | 8篇 |
预防医学 | 47篇 |
眼科学 | 4篇 |
药学 | 60篇 |
中国医学 | 1篇 |
肿瘤学 | 125篇 |
出版年
2023年 | 3篇 |
2022年 | 3篇 |
2021年 | 16篇 |
2020年 | 9篇 |
2019年 | 20篇 |
2018年 | 21篇 |
2017年 | 15篇 |
2016年 | 16篇 |
2015年 | 24篇 |
2014年 | 29篇 |
2013年 | 41篇 |
2012年 | 50篇 |
2011年 | 58篇 |
2010年 | 41篇 |
2009年 | 30篇 |
2008年 | 40篇 |
2007年 | 22篇 |
2006年 | 20篇 |
2005年 | 41篇 |
2004年 | 28篇 |
2003年 | 33篇 |
2002年 | 18篇 |
2001年 | 16篇 |
2000年 | 7篇 |
1999年 | 12篇 |
1998年 | 5篇 |
1997年 | 7篇 |
1996年 | 6篇 |
1995年 | 4篇 |
1994年 | 3篇 |
1993年 | 4篇 |
1992年 | 5篇 |
1991年 | 7篇 |
1990年 | 12篇 |
1989年 | 7篇 |
1988年 | 16篇 |
1987年 | 12篇 |
1986年 | 8篇 |
1985年 | 6篇 |
1984年 | 10篇 |
1983年 | 8篇 |
1982年 | 7篇 |
1981年 | 4篇 |
1980年 | 5篇 |
1979年 | 7篇 |
1978年 | 3篇 |
1977年 | 1篇 |
1976年 | 1篇 |
1975年 | 3篇 |
1974年 | 1篇 |
排序方式: 共有765条查询结果,搜索用时 15 毫秒
761.
Yoshiaki Maru Naotake Tanaka Keiko Ebisawa Akiko Odaka Takahiro Sugiyama Makiko Itami Yoshitaka Hippo 《Cancer science》2019,110(9):2992-3005
Cervical clear cell carcinoma (cCCC) constitutes an extremely rare subtype of cervical cancer. Consequently, its pathogenesis remains largely unknown, with no cell lines established from primary tumors. Here, we report the first establishment of cCCC organoids, from biopsy samples of a 23‐year‐old patient diagnosed with cCCC. By applying a protocol that we recently optimized for gynecological tumors, we were able to propagate a patient‐derived cell line (PDC) for more than 6 months as organoids. This PDC tolerated cryopreservation and proliferated either as spheroids or adherent cells, and developed xenografts in immunodeficient mice, ensuring robust utility as a cell line. Intriguingly, the resected tumor focally contained serous carcinoma (SC) in a tiny protruding lesion. Both organoids and derivative xenografts resembled the CCC component of the original tumor in histology, immunostaining profile, and genome‐wide copy number changes, including focal gain of MET. Genomic analysis revealed that both organoids and the CCC component harbored only a few mutations, of which 2 mutations were shared in common. In contrast, the SC component showed a mutator‐phenotype and prominent genome instability along with biallelic inactivation of TP53, but none of them were found in organoids or the CCC component. The PDC proved sensitive to major chemotherapeutic agents and MET inhibitors. These observations clearly indicated that the PDC, designated as YMC7, can be used as a novel cCCC cell line and provide novel insights into the pathogenesis of mixed cervical adenocarcinoma. As a valuable resource for rare cancer, it will likely contribute to investigations in many fields. 相似文献
762.
OBJECTIVES: Investigate cognitive, educational, and perceptual motor skills up to 2 years posttransplant of pediatric hematopoietic progenitor cell transplantation (HPCT) survivors and their correlates. METHODS: Survivors were assessed at baseline, 12, and 24 months after transplant. RESULTS: Performance IQ improved over time and was negatively related to maternal depression. Full IQ and educational outcomes were positively related to child's age and mother's age. Low depression scores were associated with high Verbal IQ one and 2 years post-HPCT, and with high visual motor scores 2 years post-HPCT. Poor educational outcomes were related to increased time since diagnosis. Two years post-HPCT, Performance IQ and Processing Speed were above the norm values whereas arithmetic and motor scores were below. CONCLUSIONS: Pediatric HPCT survivors do better cognitively than educationally. Maternal age and depression, child's age, and time since diagnosis are critical factors for these outcomes. 相似文献
763.
Brouquet A Overman MJ Kopetz S Maru DM Loyer EM Andreou A Cooper A Curley SA Garrett CR Abdalla EK Vauthey JN 《Cancer》2011,117(19):4484-4492
BACKGROUND:
Patient outcomes following resection of colorectal liver metastases (CLM) after second‐line chemotherapy regimen is unknown.METHODS:
From August 1998 to June 2009, data from 1099 patients with CLM were collected prospectively. We retrospectively analyzed outcomes of patients who underwent resection of CLM after second‐line (2 or more) chemotherapy regimens.RESULTS:
Sixty patients underwent resection of CLM after 2 or more chemotherapy regimens. Patients had advanced CLM (mean number of CLM ± standard deviation, 4 ± 3.5; mean maximum size of CLM, 5 ± 3.2 cm) and had received 17 ± 8 cycles of preoperative chemotherapy. In 54 (90%) patients, the switch from the first regimen to another regimen was motivated by tumor progression or suboptimal radiographic response. All patients received irinotecan or oxaliplatin, and the majority (42/60 [70%]) received a monoclonal antibody (bevacizumab or cetuximab) as part of the last preoperative regimen. Postoperative morbidity and mortality rates were 33% and 3%, respectively. At a median follow‐up of 32 months, 1‐year, 3‐year, and 5‐year overall survival rates were 83%, 41%, and 22%, respectively. Median chemotherapy‐free survival after resection or completion of additional chemotherapy administered after resection was 9 months (95% confidence interval, 4‐14 months). Synchronous (vs metachronous) CLM and minor (vs major) pathologic response were independently associated with worse survival.CONCLUSIONS:
Resection of CLM after a second‐line chemotherapy regimen was found to be safe and was associated with a modest hope for definitive cure. This approach represents a viable option in patients with advanced CLM. Cancer 2011;. © 2011 American Cancer Society. 相似文献764.
Daisuke Hoshi Emiri Kita Yoshiaki Maru Hiroyuki Kogashi Yuki Nakamura Yasutoshi Tatsumi Osamu Shimozato Kazuyoshi Nakamura Kentaro Sudo Akiko Tsujimoto Ryo Yokoyama Atsushi Kato Tetsuo Ushiku Masashi Fukayama Makiko Itami Taketo Yamaguchi Yoshitaka Hippo 《Cancer science》2023,114(3):1165-1179
Acinar cell carcinoma (ACC) of the pancreas is a malignant tumor of the exocrine cell lineage with a poor prognosis. Due to its rare incidence and technical difficulties, few authentic human cell lines are currently available, hampering detailed investigations of ACC. Therefore, we applied the organoid culture technique to various types of specimens, such as bile, biopsy, and resected tumor, obtained from a single ACC patient. Despite the initial propagation, none of these organoids achieved long-term proliferation or tolerated cryopreservation, confirming the challenging nature of establishing ACC cell lines. Nevertheless, the biopsy-derived early passage organoid developed subcutaneous tumors in immunodeficient mice. The xenograft tumor histologically resembled the original tumor and gave rise to infinitely propagating organoids with solid features and high levels of trypsin secretion. Moreover, the organoid stained positive for carboxylic ester hydrolase, a specific ACC marker, but negative for the duct cell marker CD133 and the endocrine lineage marker synaptophysin. Hence, we concluded the derivation of a novel ACC cell line of the pure exocrine lineage, designated HS-1. Genomic analysis revealed extensive copy number alterations and mutations in EP400 in the original tumor, which were enriched in primary organoids. HS-1 displayed homozygous deletion of CDKN2A, which might underlie xenograft formation from organoids. Although resistant to standard cytotoxic agents, the cell line was highly sensitive to the proteasome inhibitor bortezomib, as revealed by an in vitro drug screen and in vivo validation. In summary, we document a novel ACC cell line, which could be useful for ACC studies in the future. 相似文献